denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: PRIME Education, LLC
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Combination therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Education, Therapy sequence, Treatment Considerations, Biological therapies, Adverse Events
Hematology Disease Topics & Pathways:
Combination therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Education, Therapy sequence, Treatment Considerations, Biological therapies, Adverse Events
Friday, December 6, 2024: 11:00 AM-2:00 PM
Room 6DE
(San Diego Convention Center)
Chair:
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Strati: Abbvie-Genmab: Consultancy; Acerta-Astrazeneca: Consultancy, Research Funding; Sobi ADC Therapeutics: Consultancy, Other: Travel, accommodations, expenses, Research Funding; Kite, a Gilead company: Consultancy, Research Funding; Roche-Genentech: Consultancy; ALX Oncology: Research Funding; Ipsen: Consultancy; Hutchison MediPharma: Consultancy; TG Therapeutics: Consultancy.
Speakers:
Manali Kamdar, MD, MBBS, University of Colorado Cancer Center
,
Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center
,
Douglas Burgoyne, PharmD, FAMCP, University of Utah
and
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Kamdar: SeaGen: Speakers Bureau; Novartis: Research Funding; Genentech: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Research Funding. Fowler: TG Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; krystle.nomie@bostongene.com: Current Employment. Strati: Abbvie-Genmab: Consultancy; Acerta-Astrazeneca: Consultancy, Research Funding; Sobi ADC Therapeutics: Consultancy, Other: Travel, accommodations, expenses, Research Funding; Kite, a Gilead company: Consultancy, Research Funding; Roche-Genentech: Consultancy; ALX Oncology: Research Funding; Ipsen: Consultancy; Hutchison MediPharma: Consultancy; TG Therapeutics: Consultancy.
Join expert faculty as they take a deep dive into the latest clinical evidence and practical considerations for treatment of complex cases of patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Informed by real-world data on top challenges regarding the selection, sequencing and integration of novel therapies in DLBCL management plans, this satellite symposium will support lymphoma care teams in examining the latest evidence, differentiating new and emerging novel CAR T-cell and bispecific antibody therapies for DLBCL and FL, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Altogether, this satellite symposium will harness real-world experiences providing DLBCL and FL care to deepen the impact of the education, utilizing a case-based approach to provide a basis for discussion and strategy of the optimal integration of novel therapies to enhance patient-centered care and improve outcomes.
See more of: Friday Satellite Symposia